Kondo T, Mizuno Y
Table I [i] PIO pioglitazone, GLP-1R glucagon-like peptide 1 receptor, SGLT2 sodium-glucose co-transporters 2, TOFO tofogliflozin, SUL sulfonylurea, MET metformin, DAPA dapagliflozin, EXE exenatide, NAFLD non-alcoholic fatty liver disease, T2D type 2 diabetes, A1C glycated hemoglobin, ALT alanine aminotransferase, AST aspartate aminotransferase, -GT gamma-glutamyl transferase, MRI-PDFF MRI-proton density fat fraction, MRE-LSM MR elastography-liver stiffness, RCT randomized controlled trial, EDICT Efficacy and Durability of Initial Combination Therapy, CAP controlled attenuation parameter, LSM liver stiffness measurement, BMI body mass index
Many patients wonder whether bumping up their shot by a single day poses any real risk, but the answer depends on your current dose level and overall treatment plan
They exhibited a hydrodynamic diameter of 60100 nm
however, owing to the imperfect nature of the relationship between T1 and T2 relaxation times, multivariable regression models predicting NP-T2 differed than models predicting NP-T1 (Supplemental Material 2)
Contact Novo Nordisk's international patient support at novonordisk.com
